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Abstract
Introduction: Standard measurements used to assess murine models of rheumatoid arthritis, notably paw thickness 
and clinical score, do not align well with certain aspects of disease severity as assessed by histopathology. We tested 
the hypothesis that non-invasive optical tomographic imaging of molecular biomarkers of inflammation and bone 
turnover would provide a superior quantitative readout and would discriminate between a disease-modifying anti-
rheumatic drug (DMARD) and a non-DMARD treatment.
Methods: Using two protease-activated near-infrared fluorescence imaging agents to detect inflammation-associated 
cathepsin and matrix metalloprotease activity, and a third agent to detect bone turnover, we quantified fluorescence in 
paws of mice with collagen antibody-induced arthritis. Fluorescence molecular tomographic (FMT) imaging results, 
which provided deep tissue detection and quantitative readouts in absolute picomoles of agent fluorescence per paw, 
were compared with paw swelling, clinical scores, a panel of plasma biomarkers, and histopathology to discriminate 
between steroid (prednisolone), DMARD (p38 mitogen-activated protein kinase (MAPK) inhibitor) and non-DMARD 
(celecoxib, cyclooxygenase-2 (COX-2) inhibitor) treatments.
Results: Paw thickness, clinical score, and plasma biomarkers failed to discriminate well between a p38 MAPK inhibitor 
and a COX-2 inhibitor. In contrast, FMT quantification using near-infrared agents to detect protease activity or bone 
resorption yielded a clear discrimination between the different classes of therapeutics. FMT results agreed well with 
inflammation scores, and both imaging and histopathology provided clearer discrimination between treatments as 
compared with paw swelling, clinical score, and serum biomarker readouts.
Conclusions: Non-invasive optical tomographic imaging offers a unique approach to monitoring disease 
pathogenesis and correlates with histopathology assessment of joint inflammation and bone resorption. The specific 
use of optical tomography allowed accurate three-dimensional imaging, quantitation in picomoles rather than 
intensity or relative fluorescence, and, for the first time, showed that non-invasive imaging assessment can predict the 
pathologist's histology inflammation scoring and discriminate DMARD from non-DMARD activity.
Introduction
Rheumatoid arthritis (RA) is a chronic destructive
inflammatory disease of the joints. Although the disease
pathogenesis remains unclear, there is significant evi-
dence implicating T cells and B cells in the early initiating
steps of disease and innate immunity in its chronic, slow
progression [1]. Both genetic and environmental factors
contribute to the development of RA [2], and the disease
shows a steady progression of synovial hyperplasia and
neovascularization, mixed mononuclear and granulocytic
cellular infiltration, damage to articular cartilage, bone
remodeling, and proliferation of both synovial and
extraarticular fibroblasts [1,3]. This manifests clinically as
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swelling, erythema, and pain, and can progress to
decreased bone density and obvious joint architecture
changes.
Of current importance in the development of anti-
arthritic drugs is the ability to discriminate between dis-
ease-modifying anti-rheumatic drugs (DMARDs), which
affect arthritis pathogenesis and progression, and non-
DMARDs, which may show palliative effects and symp-
tom relief in the absence of affecting disease progression.
DMARD treatments include antiproliferative drugs (for
example, leflunamide and methotrexate) or cytotoxic
drugs (azathioprine) as well as agents that interfere with
TNFα, such as anti-TNF biologics (adalumimab, etaner-
cept, infliximab). Inhibitors of p38 mitogen-activated
protein kinase (MAPK) have also been shown to reduce
TNF levels and affect disease pathogenesis in animal
models of RA [4-8], with some more modest effects in
patients showing DMARD efficacy [4,9] limited by dose-
dependent toxicity. Whereas p38 MAPK inhibitors signif-
icantly decrease underlying inflammation and bone
destruction, cyclooxygenase-2 (COX-2) inhibitors, such
as celecoxib, and other nonsteroidal anti-inflammatory
drugs (NSAIDs) are better at providing symptom relief
than at altering disease progression [10,11].
A variety of rodent arthritis models have been used to
study arthritis disease progression and the impact of
promising new therapies [12]. These models include the
current gold standard approaches using type II collagen-
induced arthritis in both the mouse and rat, and have
been used extensively for benchmarking novel therapies
while being routinely validated against current standards
of care (methotrexate and prednisolone). Their utility is
limited, however, as mouse collagen-induced arthritis
models require specific disease-susceptible inbred mouse
strains (that is, DBA/1 and B10.RIII) in order to develop
arthritis, placing a heavy emphasis on the early inductive
phase of disease. In contrast, newer models that bypass
the cognate immunity step in disease induction by using
inducing antibodies to trigger chronic disease, such as the
collagen antibody-induced arthritis (CAIA) model, pro-
vide a more straightforward and rapid means of produc-
ing disease pathology that is both independent of the
mouse strain and can be used with transgenic or knock-
out mice [13-16]. Although the mouse CAIA model does
not have the extensive history and therapeutic validation
of the collagen-induced arthritis model, there is growing
support for the relevance of autoantibodies in mouse
arthritis [17-23] and in human arthritis [24-27], and there
is particular evidence suggesting the importance of
autoantibodies at disease onset [28].
Regardless of the particular rodent model used to study
disease mechanisms, current non-invasive standard read-
outs of disease severity - such as paw thickness/volume or
clinical score grades - do not provide a quantitative bio-
logical readout of the cellular/tissue-specific processes
contributing to disease progression. For instance, paw
thickness uses dimensional changes in the paw as a surro-
gate marker for underlying edema and inflammation,
while clinical score assessment is a subjective assessment
of paw swelling and erythema. Although these readouts
can be useful measures of disease severity, they empha-
size the edema component of disease rather than the
underlying synovial proliferation, inflammatory cell infil-
tration and, osteoclast-mediated bone resorption. Paw
swelling or clinical scores therefore do not discriminate
well between DMARD and non-DMARD treatments
such as NSAIDs. For instance, the non-DMARD anti-
inflammatory COX-2 inhibitors (a type of NSAID) rou-
tinely demonstrate efficacy in a variety of rodent arthritis
models, as determined by paw swelling/clinical score [5-
7,12,29,30]. Because of this, there is significant reliance
upon (terminal) histopathology to discriminate DMARD
activity from NSAID activity when assessing new drugs.
In the present article, we build upon recent advances in
optical tomographic imaging and near-infrared (NIR)
agents [31-36] to test the hypotheses that biological imag-
ing of molecular optical biomarkers of inflammation and
bone turnover would provide superior non-invasive
(nonterminal), quantitative readouts for underlying dis-
ease pathology, and that - when used in combination with
optical tomographic imaging - the CAIA model should
provide robust and quick discrimination between
DMARD and non-DMARD treatments.
Our studies illustrate the ability of three-dimensional
fluorescence molecular tomographic (FMT) quantifica-
tion to discriminate between DMARD and non-DMARD
effects. For instance, neither clinical score, paw thickness,
nor multiple plasma biomarkers could differentiate
between a p38 MAPK inhibitor and the COX-2 inhibitor
celecoxib, while FMT quantification using NIR agents to
detect cathepsin, matrix metalloprotease (MMP), or bone
resorption activity yielded a clear discrimination between
these two classes of treatment. FMT results agreed well
with histopathologic scoring of inflammation, and both
FMT and histology measures identified clear deficiencies
in clinical score and paw-swelling assessments of disease.
Optical tomographic imaging of disease biology offers a
non-invasive, nonterminal measure of disease that
strongly correlates with the underlying pathology of the
CAIA model and allows for discriminating between
DMARD and non-DMARD therapeutics.
Materials and methods
Experimental animals
Specific pathogen-free female BALB/c mice (4 to 6 weeks
o f  a g e ,  1 8  t o  2 0  g )  w e r e  o b t a i n e d  f r o m  C h a r l e s  R i v e r
(Wilmington, MA, USA) and were housed in a controlled
environment (72°F; 12 h:12 h light-dark cycle) under spe-Peterson et al. Arthritis Research & Therapy 2010, 12:R105
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cific-pathogen free conditions with water and food pro-
vided  ad libitum. All experiments were performed in
accordance with VisEn IACUC guidelines for ethical ani-
mal care and use.
Therapeutic studies with the collagen antibody-induced 
arthritis animal model
BALB/c mice were injected intravenously with 4 mg
arthrogen-collagen-induced arthritis monoclonal anti-
body cocktail (Clones D1, F10, A2 and D8 to collagen
type II; Chemicon, Temecula, CA, USA), according to the
manufacturer's instructions. Measurable morphological
changes were determined by paw thickness measurement
using a digital Vernier caliper (VWR, West Chester, PA,
USA) on days 4, 6, and 8. Observational clinical scores
(scale from 0 to 3) were also made based upon the follow-
ing criteria of redness and swelling: 0 = no swelling or
redness (normal paws), 1 = swelling and/or redness in
one digit or in the ankle, 2 = swelling and/or redness in
one or two digits and ankle, and 3 = entire paw is swollen
or red.
Beginning on day 3 post antibody cocktail injection
(prior to signs of disease), cohorts of CAIA mice (n = 12
per group) were treated daily (8 or 15 days) with either
prednisolone (10 mg/kg per oral, twice daily), a p38
MAPK inhibitor (SD0006; 15 mg/kg per oral, twice daily),
and celecoxib (15 mg/kg per oral, twice daily). Two addi-
tional groups, healthy mice (n = 12) and arthritic mice (n
= 12), received vehicle treatment only (0.5% aqueous
methyl cellulose and 0.025% Tween-80) and served as
controls.
Fluorescent agents for the detection of inflammation
Three commercially available imaging agents (VisEn
Medical Inc., Bedford, MA, USA) were used to measure
disease and therapeutic efficacy in CAIA. For assessing
the inflammatory infiltrate, two NIR protease-activatable
agents were used, one activated by cathepsins
(ProSense750) and the other activated by a family of
MMPs (MMPSense680), including MMP-3, MMP-9, and
MMP-13. These agents were administered via intrave-
nous route (2 nmol (fluorophore) in 150 μl saline) in all
imaging studies. A third NIR imaging agent that detects
changes in bone associated with disease (OsteoSense680)
was used to image and quantify bone loss. For
MMPSense680 and OsteoSense680, the 2 nmol dose of
fluorophore corresponds to 2 nmol substrate or
pamidronate, respectively. For ProSense750, the 2 nmol
dose of fluorophore corresponds to ~0.1 nmol substrate.
Imaging arthritis disease progression
CAIA and control mice were injected intravenously with
ProSense750 or MMPSense680 on day 7 following injec-
tion of collagen antibody cocktail. OsteoSense680 was
injected in additional studies on both day 7 and day 14. At
the time of imaging (24 h post agent injection), mice were
anesthetized using an intraperitoneal injection of ket-
amine (100 mg/kg) and xylazine (20 mg/kg). CAIA and
control mice were then imaged with the FMT 2500™ fluo-
rescence tomography in vivo imaging system (VisEn
Medical) using fluorescence tomographic scanning capa-
bilities as described previously [37]. Briefly, the anesthe-
tized mice were carefully positioned in a prone position
in the imaging cassette. Both hind paws were elevated on
a resin block (designed to mimic optical scattering and
absorption properties of the mouse's body) to allow larger
tomographic scanning fields for simultaneous imaging of
both paws. A NIR laser diode transilluminated the hind-
paws, with signal detection occurring via a thermoelectri-
cally cooled charge-coupled device camera placed on the
opposite side of the imaged animal. Appropriate optical
filters allowed collection both of fluorescence and excita-
tion datasets, the entire imaging acquisition requiring 4
to 5 minutes per mouse.
Fluorescence molecular tomographic reconstruction and 
analysis
The collected fluorescence data were reconstructed by
FMT 2500 system software (TruQuant™; VisEn Medical)
for the quantification of the fluorescence signal within
the paws. Three-dimensional regions of interest were
drawn to encompass each foot and subregions of the foot.
A threshold was applied identically to all animals equal to
twice the mean paw fluorescence (nanomolar) of the con-
trol, nonarthritic mice to minimize low-intensity, back-
ground fluorescence. The total amount of ankle, midfoot,
toes or total paw fluorescence (in picomoles) was auto-
matically calculated relative to internal standards gener-
ated with known concentrations of appropriate NIR dyes.
For visualization and analysis purposes, the FMT 2500
system software provided three-dimensional images and
tomographic slices.
Histopathology
The right ankle from each animal was fixed in 10% neu-
tral buffered formalin for 24 hours at 20°C, followed by
decalcification in Immunocal™ (Decal Chemical Corpora-
tion, Tallman, NY, USA) for 7 days at 20°C. Decalcified
joints were then paraffin embedded, sectioned twice (4
μm each), and stained with H & E for general evaluation
or toluidine blue for specific assessment of cartilage
changes. The ankles were evaluated via histopathology
and scored for inflammation, cartilage damage, pannus
and bone resorption according to previously published
criteria [38].
For inflammation, scores were as follows: 0 = normal, 1
= minimal infiltration of inflammatory cells in the syn-
ovial and/or periarticular tissues, 2 = mild infiltration
w i t h  m i l d  e d e m a ,  3  =  m o d e r a t e  i n f i l t r a t i o n  ( i n c l u d i n gPeterson et al. Arthritis Research & Therapy 2010, 12:R105
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joint space) with moderate edema, 4 = marked infiltration
with marked edema, and 5 = severe infiltration with
severe edema.
For cartilage damage, scores were as follows: 0 = nor-
mal, 1 = loss of toluidine blue staining with no chondro-
cyte degeneration/loss and/or matrix disruption, 2 = loss
of toluidine blue staining with minimal chondrocyte
degeneration/loss and/or mild matrix disruption in some
affected joints, 3 = loss of toluidine blue staining with
moderate chondrocyte loss and obvious (depth to deep
zone) matrix loss in affected joints, 4 = loss of toluidine
blue staining with marked (depth to tide mark) chondro-
cyte and matrix loss, and 5 = loss of toluidine blue stain-
ing with severe (depth to subchondral bone) chondrocyte
loss and matrix loss in affected joints.
For bone resorption, scores were as follows: 0 = normal,
1 = minimal (small areas of resorption in the medullary
trabecular or cortical bone, not readily apparent on low
magnification, and rare osteoclasts), 2 = mild (increasing
a r e a s  o f  r e s o rp t i o n  i n  m ed u l l a ry  t r a bec u l a r  o r  c o rt i ca l
bone, not readily apparent on low magnification, with
osteoclasts more numerous), 3 = moderate (obvious
resorption of the medullary trabecular and cortical bone,
without full-thickness defects, lesion apparent on low
magnification, and osteoclasts more numerous), 4 =
marked (full-thickness defects in the cortical bone,
marked loss of medullary trabecular bone, numerous
osteoclasts), and 5 = severe (full-thickness defects in the
cortical bone, severe loss of medullary trabecular bone).
Immunoassay analysis of plasma biomarkers
Plasma MMP-3, a soluble marker for joint pathology, was
quantified by the R&D System (Minneapolis, MN, USA)
Quantikine mouse MMP-3 (total) Immunoassay (catalog
number MMP300) according to the manufacturer's
instructions. Plasma cytokines and chemokines - eotaxin,
granulocyte colony-stimulating factor (G-CSF), granulo-
cyte-macrophage colony-stimulating factor, GRO/KC,
IFNγ, leptin, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-
10, IL-12p70, IL-13, IL-17, IL-18, IP-10, MCP-1, MIP-1β,
RANTES, TNFα and vascular endothelial growth factor -
were assessed using a multiplex Luminex-based assay
from Millipore (catalog number MPXMCYTO-70K-
PMX24; Billerica, MA USA) with the addition of 1×
Complete®  protease inhibitor cocktail (catalog number
11697498001; Roche, Indianapolis, IN, USA).
Statistical analysis
Data are presented as the mean ± standard error of the
mean. Significance analysis of in vivo paw fluorescence
was conducted using a two-tailed unpaired Student t test
when two groups were analyzed or a one-tailed analysis
of variance Scheffe multiple-comparison post test. P  <
0.05 was considered significant.
Results
Standard measures of CAIA progression (paw edema and 
clinical scoring) do not separate DMARD from non-DMARD 
treatments
To assess whether mouse CAIA can be used to effectively
discriminate between DMARD and non-DMARD treat-
ments, BALB/c mice were injected with a cocktail of anti-
collagen type II antibodies, boosted with lipopolysaccha-
ride on day 3, and treatments were initiated on day 4.
Prednisolone (as a steroid), a p38 MAPK inhibitor [8] (as
a DMARD treatment), and the non-DMARD COX-2
inhibitor celecoxib (an NSAID) were used to characterize
different classes of treatments. Animals were treated
throughout the study until the peak of disease on day 8.
Nondiseased controls, vehicle, and treated mice were
assessed for changes in paw thickness and clinical score
on days 4, 6, and 8.
The disease incidence (Figure 1a) was 92% in the vehi-
cle group, with 90% of individual arthritic paws showing a
clinical score ≥1 by day 8. Treatment groups showed
comparable kinetics and incidence of disease. Predniso-
lone treatment, as a strong positive control, effectively
ablated the clinical score (Figure 1b) and paw swelling
(Figure 1c) endpoints as early as day 6 post disease induc-
tion, maintaining this effect through to the end of the
study. The p38 MAPK inhibitor showed mild, but signifi-
cant, inhibition of clinical score at day 6, with an increase
in efficacy by day 8; and celecoxib showed a similar trend,
albeit with less overall effect by day 8. All treatments
showed highly significant inhibition of paw swelling (Fig-
ure 1c). The clinical scoring and paw swelling readouts
thus poorly discriminated between the different types of
treatments.
Histopathology and biomarker assessment of CAIA and 
treatment efficacy
Histopathologic assessment of vehicle-treated mice
revealed edema and inflammatory cell influx (general
inflammation) in the synovial tissues, joint spaces and
extra-articular soft tissues, in addition to mild articular
cartilage damage, mild osteoclast-mediated bone resorp-
tion, and extraarticular fibroplasia; no appreciable pan-
nus formation was observed in this model (Figure 2a).
These results were as expected for this acute model of
antibody-induced arthritis. Prednisolone treatment
ablated all microscopic evidence of disease (Figure 2b),
whereas celecoxib showed no reduction in edema,
inflammation or bone resorption (Figure 2c). The p38
MAPK inhibitor decreased edema and inflammatory cell
infiltration, particularly within the joint space, compared
with vehicle-treated and celecoxib-treated groups (Figure
2d).
There was a statistically significant decrease in general
inflammation histopathology scores in both the predni-Peterson et al. Arthritis Research & Therapy 2010, 12:R105
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solone and p38 MAPK inhibitor-treated groups, but not
in the celecoxib-treated group (Figure 3a). Cartilage dam-
age and osteoclast-mediated bone resorption was mild in
the vehicle-treated group (Figure 3b and 3c, respectively),
as expected in this acute and rapid model. Most notably,
statistically significant decreases were only observed in
prednisolone-treated mice.
Plasma samples from control, vehicle, and treated mice
were analyzed for levels of MMP-3 as well as a variety of
cytokines and chemokines (eotaxin, G-CSF, granulocyte-
macrophage colony-stimulating factor, GRO/KC, IFNγ,
leptin, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-
12p70, IL-13, IL-17, IL-18, IP-10, MCP-1, MIP-1β,
RANTES, TNFα and vascular endothelial growth factor).
The majority of the plasma cytokine/chemokine panel
showed either very low levels or no appreciable pattern of
change (data not shown). We detected significant plasma
elevations of only IL-6, G-CSF, and MMP-3 at day 8 (peak
disease) in the mouse CAIA model when compared with
naïve animals (Figure 4b to 4d). Eotaxin plasma levels,
although showing no increase in vehicle-treated animals,
decreased significantly with celecoxib and p38 MAPK
inhibitor treatments, but not with prednisolone treat-
ment (Figure 4a). IL-6 and G-CSF biomarkers increased
in CAIA and were significantly decreased by all treat-
ments to a similar extent (Figures 4b, c). In contrast, dis-
ease-related increases in plasma MMP-3 were decreased
~50% by all treatments with minimal statistical signifi-
cance. Plasma levels of IL-6, G-CSF, and MMP-3 at day 8
did not discriminate between DMARD and non-DMARD
treatments (Figure 4b to 4d), and no disease-related ele-
vations of these biomarkers were observed on day 15 of
disease (data not shown).
Tomographic imaging provides a clear discrimination of 
arthritis disease severity
To assess the relative benefits of optical imaging of CAIA,
w e  i m a g e d  u n t r e a t e d  a n d  c o n t r o l  m i c e  a t  t h e  p e a k  o f
inflammatory disease (day 8) using a three-dimensional
FMT imaging approach. In this study, intravenous injec-
tion of a cathepsin-activatable agent, ProSense750,
allowed the detection of activated inflammatory cells (for
example, monocytes, lymphocytes) within the joints and
paws of arthritic mice, confirming the findings of other
researchers using only semiquantitative two-dimensional
surface FRI imaging [33,36,39]. We built upon these ear-
lier observations by assessing three-dimensional FMT
imaging and quantification of arthritic mouse paws (in
units of picomoles rather than relative fluorescence
units), revealing quantitative 30-fold to 40-fold increases
in the level of fluorescent signal as compared with control
mice (Figure 5a, b).
FMT imaging offered clear advantages in the depth of
detection throughout the paw and ankle, as shown by
tomographic slices and the ability to clearly establish a
pattern of disease with a significantly larger region of
inflammation in the ankles than in the rest of the arthritic
paw (Figure 5b). Importantly, non-invasive tomographic
fluorescence imaging not only detected the inflammation
based on increased protease activity, generating three-
dimensional tissue images and tomographic slices, but
also provided accurate quantification of this fluorescence
(Figure 5c). FMT measured a >40-fold increase in
Figure 1 Disease incidence, clinical score, and paw thickness readouts of treated and untreated CAIA mic. (a) Disease incidence in control and 
treated collagen antibody-induced arthritis (CAIA) mice (n = 12 mice per group), defined as any animal showing a clinical score ≥1 in at least one paw. 
(b) Average clinical score values of all paws for control and treated CAIA mice (n = 12 mice per group). (c) Average changes in paw thickness from day 
4 to day 8 for control and treated CAIA mice. Study is representative of three separate experiments. #P < 0.05, ***P < 0.0001.
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ProSense750 fluorescence in the ankles and midfoot of
arthritic mice (~100 pmol/ankle) as compared with those
of control mice (<5 pmol/ankle) (Figure 5c). In the toe
regions, disease was localized to a smaller anatomical
area, showing less overall signal and only ~20-fold
increased over controls in the toe regions of the hind-
paws.
Optical tomographic imaging of CAIA mice treated with 
DMARD and non-DMARD therapeutics
As clinical scoring, paw swelling, and plasma biomarkers
were not very effective at detecting the differences
between DMARD and non-DMARD therapeutics when
compared with the histological assessment of inflamma-
tion, we used our NIR imaging agents to detect, image,
and quantify the protease activity associated with the
inflammatory cells in the affected tissue. Such an
approach, by virtue of direct labeling of the inflammatory
cells, should provide a superior means of assessing thera-
peutic efficacy comparable with that obtained by histopa-
thology scoring. To achieve this, the study subjects
described in Figure 1 were injected intravenously with
ProSense750 and MMPSense680 on day 7 for imaging on
day 8.
Tomographic slices of paw imaging acquired by FMT
showed a high fluorescence signal in vehicle-treated mice
as compared with those of controls (Figure 6a, b), and, in
support of our contention, the different classes of thera-
Figure 2 Histology of treated and untreated collagen antibody-induced arthritis mice. (a) Collagen antibody-induced arthritis (CAIA)/vehicle 
mouse interphalangeal joint (10× magnification) showing expansion of synovial and extraarticular tissues, as well as the joint spaces, by edema and 
inflammatory cell infiltrates (asterisks). Inset: higher magnification (40×) view of osteoclast-mediated bone resorption (arrow). (b) Prednisolone-treat-
ed mouse interphalangeal joint (10× magnification) with normal synovial tissue and cartilage. Inset: high magnification view (40×) showing absence 
of bone resorption. (c) Celecoxib-treated mouse interphalangeal joint (10× magnification) also with inflammatory cells in the joint capsule, synovium, 
and joint space (asterisks). Inset: higher magnification (40×) view of osteoclast-mediated bone resorption (arrow). (d) p38 mitogen-activated protein 
kinase (MAPK) inhibitor-treated mouse interphalangeal joint (10× magnification) with mildly decreased edema and inflammation in the joint space 
(asterisks) as compared with vehicle and celecoxib groups. Inset: higher magnification (40×) view showing inflammation (arrow) but minimal apparent 
osteoclast-mediated bone resorption. Histology assessment is representative of two separate experiments.





50 micron
50 micron 50 micron
50 micron

 
200 micron 200 micron
200 micron 200 micron
(a)
(c) (d)
(b)Peterson et al. Arthritis Research & Therapy 2010, 12:R105
http://arthritis-research.com/content/12/3/R105
Page 7 of 13
peutics showed differential effects on overall paw fluores-
cent signal. Prednisolone treatment, as a positive control,
showed a clear ablation of both cathepsin and MMP sig-
nals across all tomographic slices through the ankle, mid-
foot, and toe regions, suggesting the complete absence of
disease. Similarly, the p38 MAPK inhibitor dramatically
decreased the signal throughout most of the paw, with
higher apparent effects on the ankle and midfoot than in
the toes. In contrast to the effects of the p38 MAPK
inhibitor, celecoxib treatment had no obvious effect on
the cathepsin and MMP signals in any paw region. Tomo-
graphic imaging - in contrast to clinical scoring, paw
swelling and plasma biomarker measures - thus discrimi-
nated effectively between p38 MAPK inhibitor and cele-
coxib treatments, and revealed the paw subregions
showing predominant therapeutic impact.
Correlation of quantitative tomography, clinical scores and 
paw swelling with histopathology
Tomographic quantification of ankle, midfoot, and toe
fluorescence in treated and untreated animals showed
clear and statistically significant differences in the
ProSense750 signal (Figure 7a) and the MMPSense680
signal (Figure 7b) in the ankle and midfoot regions upon
p38 MAPK inhibitor treatment, confirming the visual dif-
ferences in tomographic slices (Figure 6). Only predniso-
lone showed efficacy in the mild inflammation of the toe
region of the arthritic mice. Quantification of imaging
datasets revealed an excellent ability to distinguish
between a p38 MAPK inhibitor and celecoxib treatments
when compared with histopathology (Figure 3a).
To better understand which CAIA readouts align best
with the underlying inflammation, the readouts for indi-
vidual paws from animals in each treatment were clus-
Figure 3 Histopathology scoring. Hindpaw tissues (n = 12 per group, one paw from each mouse) from the study represented in Figure 1 were pro-
cessed for histopathology assessment. (a) Histopathology severity scores for general inflammation. (b) Histopathology severity scores for cartilage 
damage. (c) Histopathology severity scores for osteoclast-mediated bone resorption. Histology scoring results are representative of two separate ex-
periments. *P < 0.01, **P < 0.001; ns, not significant. MAPKi, mitogen-activated protein kinase inhibitor.
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< 0.05, *P < 0.01, **P < 0.001; ns, not significant. MAPKi, mitogen-activated protein kinase inhibitor.
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tered according to their histopathology inflammation
scores (from 0 to 4). For each cluster, the average values
from optical tomography (cathepsin, MMP), clinical
scores, and paw swelling were determined and graphed in
comparison with inflammation scores (Figure 8a to 8d).
Excellent linear relationships with inflammation scoring
were seen with total paw cathepsin (Figure 8a) and MMP
(Figure 8b) activity quantification, suggesting that tomo-
graphic imaging truly detected and quantified underlying
inflammation. Indeed, the non-invasive FMT results
(with either ProSense750 or MMPSense680) were able to
accurately predict the histology scores determined by the
pathologist (Figure 8e).
Figure 5 Tomographic imaging of arthritis in collagen antibody-induced arthritis mice. Arthritic and control BALB/c mice (n = 12 mice per 
group) were injected intravenously with ProSense750 on day 7 and imaged by FMT2500™ using tomographic scanning capabilities. (a) Near-infrared 
(NIR) tomographic imaging of the hind paws of a BALB/c control mouse. (b) NIR tomographic imaging of the hind paws of an arthritic collagen anti-
body-induced arthritis (CAIA) mouse with 1 mm tomographic slices shown from the right paw. (c) Quantification of tomographic hind paw fluores-
cence (picomoles) divided by ankle, midfoot, and toes of arthritic and control mice (n = 12 per group). Study is representative of three separate 
experiments. **P < 0.001.
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Figure 6 Near-infrared tomographic slices showing protease activity in paws of arthritic and treated mice. Representative paws of mice from 
each of the groups of the study represented in Figure 1 (that is, selected paws at or near the group mean) were analyzed at the level of individual 
tomographic slices to determine the pattern of fluorescence signal in the ankle, mid-foot, and toe region for each mouse. Color scale represents local 
regions of fluorescence intensity (nanomolar) concentration. (a) Axial tomographic slices of fluorescence resulting from local cathepsin activity. (b) 
Axial tomographic slices of fluorescence resulting from local matrix metalloprotease (MMP) activity. COX-2i, cyclooxygenase-2 inhibitor; MAPKi, mito-
gen-activated protein kinase inhibitor.
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Neither clinical score (Figure 8c) nor paw swelling (Fig-
ure 8d) correlations showed adequate alignment with the
inflammation scores, with the pattern of deviation from
linearity providing clear evidence that these readouts
grossly overestimate drug efficacy regardless of therapeu-
tic class. In addition, it is not surprising that plasma bio-
markers showed very poor, nonlinear relationships to
inflammation scoring, underestimating or overestimating
drug efficacy depending on the biomarker assessed (data
not shown).
Fluorescence molecular tomography quantification of 
bone changes in CAIA
To assess whether quantitative FMT imaging can detect
subtle bone changes in this acute model of arthritis, we
imaged mice using OsteoSense680, a NIR-labeled bispho-
sphonate agent that localizes in vivo to hydroxyapatite
that is exposed during bone turnover processes. This
agent has been used to detect and quantify bone morpho-
genic protein-2-induced bone growth and fracture repair
[40], as well as bone loss in ovariectomized mice [41].
Vehicle-treated animals showed approximately twofold
higher OsteoSense680 incorporation into bone as com-
pared with nondiseased controls on day 8 (Figure 9). By
day 15, OsteoSense680 incorporation further increased
to achieve a ratio of fourfold over normal control animals,
suggesting that this imaging agent can detect and quan-
tify arthritis progression. Prednisolone treatment
decreased OsteoSense680 incorporation into bone rela-
tive to vehicle controls on day 8, maintaining this differ-
ential profile on day 15 but showing a higher signal. The
p38 MAPK inhibitor treatment showed a minimal, statis-
Figure 7 Near-infrared tomographic quantification of paw subregions of arthritic and treated mice. Each individual paw (n = 24 per group) 
from the study represented in Figure 1 was analyzed to quantify the fluorescence signal in the ankle, mid-foot, and toe region for each mouse. (a) 
Tomographic quantification of regional fluorescence resulting from cathepsin activity. (b) Tomographic quantification of regional fluorescence result-
ing from local matrix metalloprotease (MMP) activity. Analysis representative of six studies using a variety of imaging agents. **P < 0.001. MAPKi, mi-
togen-activated protein kinase inhibitor.
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tically significant decrease in OsteoSense680 signal on
day 8, with improved efficacy seen by day 15. In contrast,
celecoxib showed no signs of activity by this readout at
either timepoint. The OsteoSense680 imaging results on
day 15 were thus in strong agreement with ProSense750/
MMPSense680 imaging on day 7 as regards discriminat-
ing between celecoxib and p38 MAPK inhibitor thera-
peutic efficacy.
Discussion
Various rodent models of inflammatory arthritis are used
in research and drug development, due to their similar
pathology and/or pathogenesis to human RA, their ease
of use and reproducibility, and their ability to predict
drug efficacy in humans. Although rodent models share a
number of important morphologic and immunologic fea-
tures with RA, they progress rapidly and are heavily reli-
ant upon the acute inflammatory response. Despite this,
rodent arthritis models have contributed greatly to the
overall knowledge of RA and have led to important
advances in therapeutic intervention. Yet disease assess-
ment in rodent models relies heavily upon subjective end-
points (clinical scoring and paw swelling) that emphasize
the edema component of disease and capture little or
none of the molecular processes that drive differential
cellular infiltration and/or bone resorption. Given the
emergence of new targeted molecular therapeutic agents
(reviewed in [42,43]), improved methods for reliably and
objectively detecting and quantifying disease and thera-
peutic responses without sacrificing the animal (real
time) are warranted.
Proteases play a central role in the human RA disease
process. We therefore reasoned that protease-activatable
NIR imaging agents [44,45] could serve as a sensitive
means for reporting disease initiation and therapeutic
responses. Such agents have been used to detect protease
upregulation in a number of disease states, including can-
cer [46,47], asthma [37,48], atherosclerosis [32,49], and
Figure 8 Near-infrared tomography correlation with histology inflammation scoring. The study results from individual paws from each group 
in the study (n = 12 per group, one paw per animal) represented in Figure 7 (using the total of the paw fluorescence) were sorted according to his-
tology inflammation score (0 to 4), and means of the sorted groups were calculated for clinical score, paw swelling, and fluorescence molecular to-
mography (FMT) imaging readouts. Correlation with histologic inflammation: (a) total paw cathepsin, (b) total paw matrix metalloprotease (MMP) 
activity, (c) clinical score, and (d) paw swelling. (e) Non-invasive FMT picomole values were used to predict the pathologist's histology inflammation 
scores based on the linear relationships between ProSense750 and MMPSense680 to individual paw histology inflammation scores. Results presented 
as group means ± standard error of the means. MAPKi, mitogen-activated protein kinase inhibitor.
r² = 0.989
Paw Swelling



P
a
w
 
T
h
i
c
k
n
e
s
s
 
(
m
m
)
Inflammation Score
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
01234
Clinical Score
C
l
i
n
i
c
a
l
 
S
c
o
r
e
0.0
0.5
1.0
1.5
2.0
2.5
01234
0
50
100
150
200
250
01234
Vehicle
Prednisolone
p38 MAPKi
Celecoxib
0
10
20
30
40
50
60
70
80
01234
FMT: Total Paw Standard Measures (a)
(b)
(c)
(d)
Control
F
l
u
o
r
e
s
c
e
n
c
e
 
(
p
m
o
l
)
C
a
t
h
e
p
s
i
n
M
M
P
r² = 0.999
0
1
2
3
4
01234
Inflammation Score
MMP
Cathepsin
F
M
T
 
P
r
e
d
i
c
t
e
d
 
 
I
n
f
l
a
m
m
a
t
i
o
n
 
S
c
o
r
e
Predicting Histology Inflammation (e)Peterson et al. Arthritis Research & Therapy 2010, 12:R105
http://arthritis-research.com/content/12/3/R105
Page 11 of 13
inflammation [33,36,50]. Proof-of-concept studies using a
cathepsin-activatable probe for in vivo imaging of pro-
tease activity associated with RA animal models have also
recently been published [36]. A number of issues remain
to be clarified, however, including the utility of optical
tomography to provide quantitative readouts that dis-
criminate between DMARD and non-DMARD treat-
ments, and a clear and comprehensive comparison of
imaging readouts with standard measures of clinical
score and paw swelling.
For the first time, we show the benefit of optical tomo-
graphic imaging in a mouse model of arthritis and dem-
onstrate that tomography not only can provide a
quantitative measurement of disease severity but also can
accurately define the scope of disease in the ankle joints
versus interphalangeal joints of the hindpaws (Figure 5).
The higher signal in the ankle joints probably indicates a
greater magnitude of disease rather than a significantly
greater severity of disease processes, as more total disease
activity would obviously be occurring in the larger ankle
joint. The multiplex approach to quantifying two or more
biomarkers correlated with the histopathology, and the
fluorescence data could be used to accurately predict his-
tology inflammation scores prior to collection of tissue.
These results confirmed that imaging of cathepsin activ-
ity, MMP activity, and bone turnover is a successful non-
invasive diagnostic modality, capable of providing robust
measures of disease progression.
Optical tomographic imaging of NIR imaging agents in
CAIA has the potential to be used in drug discovery
research by virtue of deep tissue penetration, quantitative
readout (picomoles rather than light intensity), and the
pairing with NIR imaging agents that detect the cellular
participants in the underlying disease pathology. Both
p38 MAPK inhibitors and COX-2 inhibitors have previ-
ously been shown to effectively reduce clinical signs of
disease and paw swelling measurements in rodent models
of arthritis [6,7,51,52]. COX-2 inhibitors and other
NSAIDs are better at providing symptom relief than at
altering disease progression [10,11], however, whereas
p38 MAPK inhibitors significantly decrease underlying
inflammation and bone destruction [4-8]. We confirmed
these observations, showing an overestimation of efficacy
of celecoxib and p38 MAPK inhibitors on clinical score
and paw swelling as compared with effects by histological
assessment (Figures 1 to 3).
A large panel of plasma biomarkers (including IL-6, G-
CSF, eotaxin, and MMP-3) also failed to accurately char-
acterize therapeutic efficacy, with both overestimation
and underestimation of observed responses (Figure 4)
depending on the specific biomarker and therapeutic
agent. Although it is likely that the failure of many of the
tested biomarkers was due to the very acute nature of this
model, it does highlight the disconnection, or perhaps
delay, of plasma biomarkers relative to vigorous onset of
joint inflammation and destruction. This very failure of
plasma biomarkers further suggests that direct imaging of
the site of disease should generally be a more accurate
means of assessing chronic progression as well as acute
flares of disease in human RA. In contrast, imaging with
either ProSense750, MMPSense680, or OsteoSense680
provided an excellent discrimination between p38 MAPK
inhibitor and celecoxib therapies (Figures 6, 7 and 9), and
correlated extremely well with histology inflammation
scores (Figure 3a) and human therapeutic observations.
In preliminary studies, we found a similar dissociation
between standard measures compared with imaging and
histology in mouse collagen-induced arthritis when mice
were imaged on day 50 post immunization (JD Peterson
and TP Misko, unpublished observations).
Imaging CAIA mice using OsteoSense680 appears to
be a rapid and sensitive means of detecting changes in
bone turnover associated with disease progression. It is
important to note that bone resorption was mild in this
acute model, as assessed by histopathology (Figures 2 and
3), yet OsteoSense680 showed a twofold increase in sig-
nal on day 8 and a fourfold increase by day 15, suggesting
significant bone changes were occurring. Furthermore,
this readout clearly differentiated between p38 MAPK
inhibitor and prednisolone as compared with celecoxib
on day 15. It is interesting to note that prednisolone
decreased the OsteoSense680 signal on day 8 to the level
of the control mice; however, on day 15 the signal
increased above the control in the absence of any appar-
Figure 9 Tomographic imaging of bone changes in collagen anti-
body-induced arthritis mice. Vehicle, control, and treated mice were 
injected intravenously with OsteoSense680 on day 7 or day 14 and 
were imaged by FMT2500™. Quantitation of tomographic hind paw 
fluorescence (picomoles) of arthritic and control mice (n = 6 per group) 
is represented for day 8 and day 15 imaging. Study is representative of 
two separate experiments. #P < 0.05, *P < 0.01, **P < 0.001; ns, not sig-
nificant. MAPKi, mitogen-activated protein kinase inhibitor.
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ent disease. The longer treatment time with prednisolone
probably induced some bone loss, as we have seen previ-
ously that this dose of prednisolone will indeed cause
some bone loss (and increased OsteoSense680 incorpora-
tion) in normal mice (JD Peterson and R Rader, unpub-
lished observations).
Conclusions
Our studies have built upon the advances in rodent
arthritis models as well as in imaging technology to
establish non-invasive optical tomographic imaging as a
robust and accurate means of assessing inflammation and
bone changes in arthritis in vivo. For the first time, strong
correlations can be shown between quantitative imaging
and underlying disease as measured by histologic scoring,
such that imaging data can be used to predict histological
findings. This technology offers a powerful tool for both
basic arthritis research as well as for drug discovery and
development by enabling the non-invasive monitoring of
cellular processes that also drive human RA pathology.
FMT thus should provide a rapid means for selecting
DMARD-like drug candidates for clinical evaluation. The
future may also bring adaptations of this technology and
agents for the monitoring of disease progression and
therapeutic intervention in human RA.
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